Wockhardt Chairman Habil Khorakiwala said, Wockhardt is one of the only three companies to have received this approval. This product required significant R&D activity in both API and injections and is a reflection of the multi-faceted capabilities of Wockhardt to meet the challenges of the US markets.”Wockhardt’s Ceftazidime injections will be launched in the US very shortly.
Ceftazidime is used in treating several kinds of infections and is one of the most potent, powerful and safe antibiotics.The Ceftazidime pentahydrate API is manufactured in the FDA approved API facility at Ankleshwar, Gujarat and the injections are manufactured at the US FDA certified formulation plant at Waluj, Maharashtra. The API and the product were developed in-house.